On Jun. 17, 2021, the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research granted approval to Sanofi Pasteur for an additional influenza manufacturing facility located in Swiftwater, PA.

The newly completed facility expanded production and distribution of Sanofi’s Fluzone High-Dose Quadrivalent for the upcoming 2021-2022 influenza season in the U.S. and up to 200 additional manufacturing jobs.